- Home
- PEBK vs KROS Comparison
PEBK vs KROS Comparison
Compare PEBK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PEBK | KROS |
|---|---|---|
| Founded | 1912 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.9M | 222.3M |
| IPO Year | 2012 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PEBK | KROS |
|---|---|---|
| Price | $42.32 | $11.29 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 24.2K | ★ 321.2K |
| Earning Date | 04-20-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | 21.48 | ★ 146.00 |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | $52.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.81 | $9.79 |
| 52 Week High | $43.31 | $22.55 |
Technical Indicators
Market Signals| Indicator | PEBK | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 62.57 | 48.57 |
| Support Level | $38.84 | $10.47 |
| Resistance Level | N/A | $12.43 |
| Average True Range (ATR) | 1.07 | 0.68 |
| MACD | 0.18 | 0.05 |
| Stochastic Oscillator | 73.38 | 59.09 |
Price Performance
Historical ComparisonAbout PEBK Peoples Bancorp of North Carolina Inc.
Peoples Bancorp of North Carolina Inc is a bank holding company. It is a state-chartered commercial bank serving Lincolnton, Newton, Denver, Catawba, Conover, Maiden, Claremont, Hiddenite, Hickory, Charlotte, Cornelius, Raleigh and Cary, North Carolina. It has a diversified loan portfolio with no foreign loans and few agricultural loans. The company's main source of income is dividends declared and paid by the Bank on its capital stock.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.